These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 12722735)

  • 21. Almotriptan: pharmacological differences and clinical results.
    Pascual J
    Curr Med Res Opin; 2001; 17 Suppl 1():s63-7. PubMed ID: 12463281
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brain stem activation in spontaneous human migraine attacks.
    Weiller C; May A; Limmroth V; Jüptner M; Kaube H; Schayck RV; Coenen HH; Diener HC
    Nat Med; 1995 Jul; 1(7):658-60. PubMed ID: 7585147
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral imitrex for migraine relief.
    Burke SM
    MCN Am J Matern Child Nurs; 1996; 21(6):316. PubMed ID: 8952287
    [No Abstract]   [Full Text] [Related]  

  • 24. BMS-181885, a 5-HT1B/1D receptor ligand, in experimental models predictive of antimigraine activity and coronary side-effect potential.
    Saxena PR; De Vries P; Heiligers JP; Bax WA; Maassen VanDenBrink A; Yocca FD
    Eur J Pharmacol; 1998 Jun; 351(3):329-39. PubMed ID: 9721025
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cranial vascular effects of zolmitriptan, a centrally active 5-HT1B/1D receptor partial agonist for the acute treatment of migraine.
    MacLennan SJ; Cambridge D; Whiting MV; Marston C; Martin GR
    Eur J Pharmacol; 1998 Nov; 361(2-3):191-7. PubMed ID: 9865508
    [TBL] [Abstract][Full Text] [Related]  

  • 26. From serotonin receptor classification to the antimigraine drug sumatriptan.
    Saxena PR; Ferrari MD
    Cephalalgia; 1992 Aug; 12(4):187-96. PubMed ID: 1326401
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Highly selective beginning. Associated symptoms and side effects in retrospect].
    MMW Fortschr Med; 2003 May; 145 Suppl 2():107. PubMed ID: 14579499
    [No Abstract]   [Full Text] [Related]  

  • 28. New insights into the molecular actions of serotonergic antimigraine drugs.
    Durham PL; Russo AF
    Pharmacol Ther; 2002; 94(1-2):77-92. PubMed ID: 12191595
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Porcine carotid vascular effects of eletriptan (UK-116,044): a new 5-HT1B/1D receptor agonist with anti-migraine activity.
    Willems E; De Vries P; Heiligers JP; Saxena PR
    Naunyn Schmiedebergs Arch Pharmacol; 1998 Aug; 358(2):212-9. PubMed ID: 9750007
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SUMATRIPTAN: a receptor-targeted treatment for migraine.
    Moskowitz MA; Cutrer FM
    Annu Rev Med; 1993; 44():145-54. PubMed ID: 8386498
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Agonist activity of antimigraine drugs at recombinant human 5-HT1A receptors: potential implications for prophylactic and acute therapy.
    Newman-Tancredi A; Conte C; Chaput C; Verrièle L; Audinot-Bouchez V; Lochon S; Lavielle G; Millan MJ
    Naunyn Schmiedebergs Arch Pharmacol; 1997 Jun; 355(6):682-8. PubMed ID: 9205951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vasoconstrictive properties of the 5HT1B/1D agonists: response to Dahlöf and Mathew.
    Goldstein D
    Cephalalgia; 1999 Jun; 19(5):536-7. PubMed ID: 10403072
    [No Abstract]   [Full Text] [Related]  

  • 33. Profiles of 5-HT 1B/1D agonists in acute migraine with special reference to second generation agents.
    Deleu D; Hanssens Y
    Acta Neurol Belg; 1999 Jun; 99(2):85-95. PubMed ID: 10427351
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The 5-HT1-like receptor mediating the increase in canine external carotid blood flow: close resemblance to the 5-HT1D subtype.
    Villalón CM; Terrón JA
    Br J Pharmacol; 1994 Sep; 113(1):13-20. PubMed ID: 7812603
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical effects and mechanism of action of sumatriptan in migraine.
    Ferrari MD; Saxena PR
    Clin Neurol Neurosurg; 1992; 94 Suppl():S73-7. PubMed ID: 1320526
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological characterization of almotriptan: an indolic 5-HT receptor agonist for the treatment of migraine.
    Bou J; Domènech T; Puig J; Heredia A; Gras J; Fernández-Forner D; Beleta J; Palacios JM
    Eur J Pharmacol; 2000 Dec; 410(1):33-41. PubMed ID: 11134654
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 5-HT7 receptors are involved in neurogenic dural vasodilatation in an experimental model of migraine.
    Wang X; Fang Y; Liang J; Yan M; Hu R; Pan X
    J Mol Neurosci; 2014; 54(2):164-70. PubMed ID: 24584680
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Sumatriptan and its use in treatment of migraine and cluster headaches].
    Prusiński A
    Neurol Neurochir Pol; 1992; Suppl 2():28-48. PubMed ID: 1337766
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Simultaneous measurement of [3H]noradrenaline release and neurogenic contraction under identical conditions, to determine the prejunctional inhibitory effects of SKF 99101H and BRL 56905 in dog saphenous vein.
    Medhurst AD; Brown AM; Kaumann AJ; Parsons AA
    Naunyn Schmiedebergs Arch Pharmacol; 1997 Apr; 355(4):475-82. PubMed ID: 9109364
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Functional profile of almotriptan in animal models predictive of antimigraine activity.
    Gras J; Bou J; Llenas J; Fernández AG; Palacios JM
    Eur J Pharmacol; 2000 Dec; 410(1):43-51. PubMed ID: 11134655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.